CD8A and neoplasm: The authors also revealed the ability of PTX‐HEs to enhance drug delivery and their ability to alter the tumor microenvironment by activating CD4+ and CD8+ T cells, polarizing macrophages towards the M1 phenotype, and reducing regulatory T cells (TRegs), thus augmenting the antitumor immune response (Figure 13E).